I've always loved the science here, but absolutely hated...

I've always loved the science here, but absolutely hated management. The big wigs "fat cat" lifestyle were lavishly paid for by shareholders in seemingly endless equity buoyancy and liquidity. "Don't worry" they thought, "By the time the next raise comes around, our share price will have doubled!"

Well now the realities of this biotech winter have set in, I believe they are finally getting paid to do some real work behind the scenes out of desperation. This is coupled with a product that would literally sell itself, and the scientific efficacy to back it up. Mind you, an 85 mil MC in a ph3 setting, you are pretty much at the lowest risk entry point for optionality as far as binary outcome biotechs can be.

I've broken my own rule here to invest in untrustworthy management. However at this price, a small investment is worth the risk. I'll put this chart up again to compare the pair. Both have great science. Both have lifestyle management. Both are cut from the same cloth. Both in ph3 trials. One has risen, so will the other?

I speculate a deal with a partner will be made.

My target is $1